Lung transplantation

Dr. Frank J. Veith Joins the Board of Directors of ViTAA Medical Solutions

Retrieved on: 
Thursday, February 29, 2024
Software, Research, General Health, Technology, Public Relations, Investor Relations, Clinical Trials, Science, Surgery, Biotechnology, Communications, Other Science, Health, Chin Na, Cleveland Clinic, University Medical Center, Harvard Medical School, Medical corps, Vascular disease, Vitaa, Brigham and Women's Hospital, Lung transplantation, Medicine, Management

ViTAA Medical Solutions, Inc., a leading innovator of precision vascular health designed to improve patient outcomes across the globe, is thrilled to announce the appointment of Frank J. Veith, M.D., a distinguished figure in the field of vascular surgery, to its Board of Directors.

Key Points: 
  • ViTAA Medical Solutions, Inc., a leading innovator of precision vascular health designed to improve patient outcomes across the globe, is thrilled to announce the appointment of Frank J. Veith, M.D., a distinguished figure in the field of vascular surgery, to its Board of Directors.
  • "We are honored to welcome Dr. Veith to our Board of Directors," said Mitchel Benovoy, CEO of ViTAA Medical Solutions.
  • Dr. Veith's addition to the Board underscores ViTAA's commitment to excellence and innovation in the development of medical technologies.
  • "I am honored and excited to join the ViTAA Board of Directors and contribute to their mission of transforming vascular care," said Dr. Veith.

Spectral AI Appoints Dr. J. Michael DiMaio to Board of Directors

Retrieved on: 
Monday, February 12, 2024
Hospital, American Heart Association, Artificial intelligence, Society, University, American College, Health, American Surgical Association, Cardiothoracic surgery, Bangladesh Technical Education Board, Register, NIH, Duke University Hospital, JAMA, Physician, MDAI, International Society, General surgery, Abstract, Internal medicine, United, Society of Thoracic Surgeons, Research, Human services, Spectral, FDA, American College of Surgeons, National Science Foundation, American Burn Association, Lung transplantation, Publication, Medical device

DALLAS, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on the unmet need for improved medical diagnostics to allow faster and more accurate treatment decisions in wound care, today announces the appointment of Dr. J. Michael DiMaio to its Board of Directors, effective February 7, 2024.

Key Points: 
  • DALLAS, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on the unmet need for improved medical diagnostics to allow faster and more accurate treatment decisions in wound care, today announces the appointment of Dr. J. Michael DiMaio to its Board of Directors, effective February 7, 2024.
  • Dr. DiMaio joins the Board as a non-executive member to fill the vacancy left by the departure of Mr. Michael Murphy.
  • Dr. Michael DiMaio is one of the Company’s founders and previously served as the Company’s Chief Executive Officer and Chairman of the Board of Directors from 2011 to 2020.
  • "I am pleased to welcome back Dr. Michael DiMaio to Spectral AI’s Board of Directors," said Richard Cotton, Chairman of the Board of Directors.

Qorvis Appoints Cardiac Surgeon, Dr. Colleen Pietras, M.D., as Chief Medical Officer

Retrieved on: 
Tuesday, February 6, 2024
Clinical professor, University, Medical school, Qorvis, Pennsylvania State University, Mayo Clinic, Heart, News, Boston University, Yale University, Lung transplantation, Russell Sage College, Health, Master, Organization, Medical device

WASHINGTON, Feb. 6, 2024 /PRNewswire/ -- Qorvis announces the appointment of Dr. Colleen Pietras, M.D., to the position of Chief Medical Officer.

Key Points: 
  • WASHINGTON, Feb. 6, 2024 /PRNewswire/ -- Qorvis announces the appointment of Dr. Colleen Pietras, M.D., to the position of Chief Medical Officer.
  • A cardiac surgeon with experience at institutions including Yale and the Mayo Clinic, Dr. Pietras will enrich the communications support Qorvis provides to clients in the healthcare, pharmaceuticals, life sciences, and medical device sectors, among others.
  • Dr. Pietras has been a cardiac surgeon and assistant professor of cardiac surgery at the Yale University School of Medicine.
  • For more information on Qorvis or how we can help you navigate the year ahead, visit www.qorvis.com .

Orphan designation: Allogeneic amniotic fluid-derived mesenchymal stem cells with lung specificity Prevention of primary graft dysfunction following lung transplantation, 13/12/2023 Positive

Retrieved on: 
Sunday, February 4, 2024
COMP, European Commission, IRIS, Allotransplantation, Committee, Lung transplantation, EMA, Pharmaceutical industry

EU/3/23/2860 - orphan designation for prevention of primary graft dysfunction following lung transplantation

Key Points: 
  • EU/3/23/2860 - orphan designation for prevention of primary graft dysfunction following lung transplantation
    Allogeneic amniotic fluid-derived mesenchymal stem cells with lung specificity
    OrphanHuman
    Amniotics AB
    For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
    European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:
    EMA list of opinions on orphan medicinal product designation
    EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:

TFF Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for Presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting

Retrieved on: 
Tuesday, January 9, 2024
Mortality, The Alfred Hospital, Lung transplantation, Lead, Heart, Tacrolimus, Immunosuppression, TFF, Lung

FORT WORTH, Texas, Jan. 09, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the acceptance of a late-breaking abstract for presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting, which will be held in Prague, Czech Republic from April 10-13, 2024.

Key Points: 
  • FORT WORTH, Texas, Jan. 09, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the acceptance of a late-breaking abstract for presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting, which will be held in Prague, Czech Republic from April 10-13, 2024.
  • “Despite the availability of numerous immunosuppressive therapies, the unmet medical need remains high in lung transplantation, which has a 5-year mortality of approximately 50%.
  • New targeted therapeutic approaches are clearly needed that can optimize immunosuppression in the lung while avoiding the dose-limiting toxicities associated with systemically administered immunosuppressive therapies,” said Professor Gregory Snell, Medical Head of Lung Transplant Service at the Alfred Hospital and Lead Principal Investigator of the Phase 2 TFF TAC trial.
  • “Initial data from the ongoing Phase 2 study suggest that TFF TAC, which delivers tacrolimus directly to the lungs, may represent a viable approach in achieving this desired balance, and I look forward to presenting initial data from the Phase 2 trial at the upcoming ISHLT 2024 meeting.”

Paragonix SherpaPak Recognized for Maximizing Access to the Donor Pool in New Clinical Study

Retrieved on: 
Tuesday, January 9, 2024
General Health, Health, Surgery, Organ transplantation, Medical University of Vienna, Patient, Risk, CTS, Medical school, Survival, Freezing, Lung transplantation, ECMO, PGD, Physician, Dentistry

The use of extended criteria donor organs can increase the availability of life-saving transplantable organs, proving to be a valuable solution to those on the waitlist in need of an organ transplant.

Key Points: 
  • The use of extended criteria donor organs can increase the availability of life-saving transplantable organs, proving to be a valuable solution to those on the waitlist in need of an organ transplant.
  • The Paragonix SherpaPak CTS is a static hypothermic preservation device intended to protect the donor heart during transit, standardizing the internal environment to maintain a recommended thermal range above freezing, unlike traditionally used ice-cold storage.
  • Published in the esteemed Journal of Heart and Lung Transplantation, this study compared the effectiveness of ice-cold storage against the Paragonix SherpaPak CTS, assessing the post-transplant outcomes of recipients who received an extended criteria donor heart.
  • “The study finds the Paragonix SherpaPak Cardiac Transport System provides a clinically effective solution to safely increase donor heart utilization.

TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC

Retrieved on: 
Tuesday, December 19, 2023
Patient, Immune system, EAP, Mortality, Disease, Lung transplantation, IPA, CLAD, Infection, Safety, Diagnosis, Phase II, History, TFF, Pharmaceutical industry

“Today is truly a remarkable moment in the history of TFF Pharmaceuticals, as these initial clinical data clearly demonstrate the efficacy and favorable safety and tolerability of TFF VORI and TFF TAC in two rare disease indications with high unmet medical need.

Key Points: 
  • “Today is truly a remarkable moment in the history of TFF Pharmaceuticals, as these initial clinical data clearly demonstrate the efficacy and favorable safety and tolerability of TFF VORI and TFF TAC in two rare disease indications with high unmet medical need.
  • “Based on these highly encouraging efficacy and safety data, we have made the decision to accelerate the development of TFF VORI and TFF TAC into registration-enabling studies, given the unequivocally positive results from these initial data.
  • Looking ahead, we expect to present additional clinical data in the first quarter of 2024 to further support the advancement of TFF VORI and TFF TAC into registration-enabling studies.”
    “These initial data provide compelling evidence that both TFF VORI and TFF TAC have game-changing potential in the treatment of their respective rare disease indication, IPA and prevention of rejection after lung transplantation,” said Zamaneh Mikhak, M.D., Chief Medical Officer of TFF Pharmaceuticals.
  • Additionally, the patients maintained their kidney function and chose to remain on TFF TAC long term.”
    The ongoing Phase 2 trial of TFF VORI is an open-label, randomized (3:1) study evaluating treatment with TFF VORI versus oral voriconazole over a 13-week period in patients with IPA.

ISHLT Elects New Board Members and Professional Community Leaders

Retrieved on: 
Friday, December 1, 2023
Lung transplantation, TDM, Chairperson, Infection, Annual, FCCP, Transplant, Tissue engineering, MBA, Pediatrics, International Society, Pulmonary heart disease, Heart transplantation, Pulmonary hypertension, Care, Society, Sarcoidosis, Research, MCS, Standard, COVID-19, Publication, Management

The Society will welcome four new members to the Board of Directors and 16 leaders across ISHLT’s professional specialty communities to serve as representatives to the 4 ISHLT Interdisciplinary Network Steering Committees and the Early Career & Trainee Committee.

Key Points: 
  • The Society will welcome four new members to the Board of Directors and 16 leaders across ISHLT’s professional specialty communities to serve as representatives to the 4 ISHLT Interdisciplinary Network Steering Committees and the Early Career & Trainee Committee.
  • Professor Josef Stehlik, MD, will serve as ISHLT President-Elect beginning in May 2024 and as ISHLT President beginning in May 2025.
  • The elected members of the Board of Directors are:
    Professor Stehlik’s areas of interest include advanced heart failure, heart transplantation, mechanical circulatory support, cardiac sarcoidosis, and cardioversion.
  • Beginning 1 May, 2024, the new composition of the Board will be:
    The elected Professional Community leaders are:

Pulmonary Fibrosis Foundation Aims to Bridge Healthcare Gaps in Rural Communities

Retrieved on: 
Friday, December 22, 2023
Outline, Risk, Multimedia, Pulmonary fibrosis, Research, Telehealth, CMO, ILD, Idiopathic pulmonary fibrosis, Lung transplantation, IPF, Health, Incidence, PFF, Patient, Palliative care, Communication, Nursing

CHICAGO, Dec. 22, 2023 /PRNewswire-PRWeb/ -- The Pulmonary Fibrosis Foundation (PFF) has published a comprehensive position statement to increase awareness of pulmonary fibrosis (PF) in rural communities and to outline the Foundation's rural health initiatives. The "Rural Outreach in Pulmonary Fibrosis" statement, comprising versions tailored for patients and healthcare providers, delineates strategies impacting patient care, research, and advocacy.

Key Points: 
  • The Pulmonary Fibrosis Foundation's new position statement addresses rural healthcare gaps, focusing on raising awareness and offering resources for people living with pulmonary fibrosis and their healthcare providers.
  • CHICAGO, Dec. 22, 2023 /PRNewswire-PRWeb/ -- The Pulmonary Fibrosis Foundation (PFF) has published a comprehensive position statement to increase awareness of pulmonary fibrosis (PF) in rural communities and to outline the Foundation's rural health initiatives.
  • The "Rural Outreach in Pulmonary Fibrosis" statement, comprising versions tailored for patients and healthcare providers , delineates strategies impacting patient care, research, and advocacy.
  • "Residents in rural communities encounter significant obstacles to healthcare access, including distance to specialized centers, communication challenges between providers, and limitations in clinical information exchange.

Hundreds of transplant patients, physicians, and health equity advocates join Honor the Gift rally on Capitol Hill to implore President Biden and HHS Secretary Becerra to immediately restore Medicare coverage of critical blood tests that detect organ tran

Retrieved on: 
Tuesday, December 5, 2023
Macs, Sibling, Patient, CMS, Infection, Cancer, Administration, Recurrence, Quality of life, Government, Travel, Educational Testing Service, Immune system, Organization, Multimedia, House, Heart, Health, Health equity, Society, Physician, Kidney, Immunosuppression, Risk, Transplant surgeon, ASTS, Organ transplantation, HHS, Medicare, International Society, Comment, Gift, Immunodeficiency, Lung transplantation, Dialysis, Left–right political spectrum, Fear, American Society of Transplantation, COVID-19, The Wall Street Journal, MD, Dentistry, Pharmaceutical industry, Hospital, Health insurance, Latino, Noridian Mutual Insurance Company, Policy, Transplant

WASHINGTON, Dec. 5, 2023 /PRNewswire/ -- Congressman Don Bacon (R-NE-02), Senator Kirsten Gillibrand (D-NY), co-sponsors of the Living Donor Protection Act, Newt Gingrich, former Speaker of the House, Reverend Al Sharpton, civil rights and social justice leader, and Al B. Sure!, universally celebrated recording artist and liver transplant recipient, joined the Honor the Gift coalition and the American Association of Kidney Patient's (AAKP) Chair of Policy and Global Affairs Paul T. Conway, and other leaders in the field for a press conference on Capitol Hill, calling on the Centers for Medicare & Medicaid Services (CMS), Health and Human Services (HHS) Secretary Xavier Becerra, and President Joe Biden to stop the current attempt by private contractors to rollback Medicare coverage for innovative molecular blood tests for transplant patients.

Key Points: 
  • The critical tests at issue help detect organ transplant rejection early and reduce the need for invasive biopsies.
  • For example, many transplant patients receive these sequential blood tests post-transplant to monitor their transplanted organ.
  • The results of each blood test can provide a potential early warning of organ transplant rejection and injury before other indicators.
  • Especially troubling is that some of these patients who have not received testing may unknowingly be suffering from asymptomatic organ transplant rejection.